Taiji Furukawa

Prof. Taiji Furukawa

Teikyo University School of Medicine

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2005 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
TFTaiji Furukawa
Taiji Furukawa
TNToshihide Nukada
Toshihide Nukada
RMReiko Miura
Reiko Miura
KOKyoji Ooga
Kyoji Ooga
MHMituyoshi Honda
Mituyoshi Honda
TITakaaki Isshiki
Takaaki Isshiki
Recent reports show that efonidipine, a dihydropyridine Ca2+ antagonist, has blocking action on T-type Ca2+ channels, which may produce favorable actions on cardiovascular systems. However, the effects of other dihydropyridine Ca2+ antagonists on T-type Ca2+ channels have not been investigated yet. Therefore, in this study, we examined the effects of dihydropyridine compounds clinically used for treatment of hypertension on a T-type Ca2+ channel subtype, α1G, expressed in Xenopus oocytes. These effects were compared with those on T-type Ca2+ channel. Rabbit L-type (α1Cα2/δβ1a) or rat T-type (α1G) Ca2+ channel was expressed in Xenopus oocytes by injection of cRNA for each subunit. The Ba2+ currents through expressed channels were measured by conventional 2-microelectrode voltage-clamp methods. Twelve DHPs (amlodipine, barnidipine, benidipine, cilnidipine, efonidipine, felodipine, manidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nitrendipine) and mibefradil were tested. Cilnidipine, felodipine, nifedipine, nilvadipine, minodipine, and nitrendipine had little effect on the T-type channel. The blocks by drugs at 10 μM were less than 10% at a holding potential of −100 mV. The remaining 6 drugs had blocking action on the T-type channel comparable to that on the L-type channel. The blocking actions were also comparable to that by mibefradil. These results show that many dihydropyridine Ca2+ antagonists have blocking action on the α1G channel subtype. The action of dihydropyridine Ca2+ antagonists in clinical treatment should be evaluated on the basis of subtype selectivity.

1 June 2009 in European Journal of Pharmacology
Verified
Journal Article
Closed access
TFTaiji Furukawa
Taiji Furukawa
TNToshihide Nukada
Toshihide Nukada
YNYoshiko Namiki
Yoshiko Namiki
YMYoriko Miyashita
Yoriko Miyashita
KHKento Hatsuno
Kento Hatsuno
TITakaaki Isshiki
Takaaki Isshiki

1 December 2004 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
TFTaiji Furukawa
Taiji Furukawa
RMReiko Miura
Reiko Miura
MHMitsuyoshi Honda
Mitsuyoshi Honda
NKNatsuko Kamiya
Natsuko Kamiya
YMYasuo Mori
Yasuo Mori
TNToshihide Nukada
Toshihide Nukada

1 December 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
ATAtsushi Tanaka
Atsushi Tanaka
AKAtsushi Kawaguchi
Atsushi Kawaguchi
HTHirofumi Tomiyama
Hirofumi Tomiyama
TITomoko Ishizu
Tomoko Ishizu
CMCHISA MATSUMOTO
CHISA MATSUMOTO
KNKoichi Node
Koichi Node

22 October 2013 in Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
TFTaiji Furukawa
Taiji Furukawa
MSMasaaki Suzuki
Masaaki Suzuki
MOMina Ochiai
Mina Ochiai
HKHideyuki Kawashima
Hideyuki Kawashima
NYNaoyuki Yokoyama
Naoyuki Yokoyama
TITakaaki Isshiki
Takaaki Isshiki

18 November 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
SNSatoshi Nishida
Satoshi Nishida
NMNaohisa Matsunaga
Naohisa Matsunaga
YKYuta Kamimura
Yuta Kamimura
SIShinobu Ishigaki
Shinobu Ishigaki
TFTaiji Furukawa
Taiji Furukawa
YOYasuo Ono
Yasuo Ono
Background: Carbapenemase-producing Enterobacteriaceae (CPE) are an emerging threat in healthcare settings worldwide. Objectives: We evaluated the presence of carbapenemase genes in CPE in a tertiary care university hospital in Tokyo, Japan. Methods: Carbapenem-resistant clinical isolates were collected in 2018 at Teikyo University Hospital (Tokyo, Japan). Bacterial species were identified using MALDI-TOF MS. Carbapenemase production was evaluated using a carbapenemase inactivation method. The presence of carbapenemase genes was confirmed by multiplex PCR and DNA sequencing. Results: Four CPE isolates were identified: two Enterobacter cloacae complex strains and Klebsiella oxytoca and Klebsiella pneumoniae strains. Three of the isolates (E. cloacae complex and K. oxytoca) were IMP-1-type producers, including IMP-10 in their produced metallo-β-lactamase, and are epidemic in East Japan. The IMP-10-producing E. cloacae complex strain also produced CTX-M ESBL. The other CPE isolate (K. pneumoniae) is a VIM-1 producer. VIM-1-producing K. pneumoniae is epidemic in Europe, especially in Greece. Accordingly, the VIM-1 producer was isolated from a patient with a medical history in Greece. Conclusions: This study revealed the emergence of E. cloacae complex co-producing IMP-1-type carbapenemase and CTX-M ESBL, and K. pneumoniae producing VIM-1 carbapenemase in clinical isolates in Japan. Metallo-β-lactamase was the most prevalent type of carbapenemase at Teikyo University Hospital, especially IMP-1-type carbapenemase. The detection of VIM-1-producing K. pneumoniae suggests that epidemic CPE from overseas can spread to countries with low CPE prevalence, such as Japan, highlighting the need for active surveillance.